Roth Capital Equities Analysts Increase Earnings Estimates for Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Roth Capital boosted their FY2027 EPS estimates for shares of Zevra Therapeutics in a research report issued to clients and investors on Wednesday, May 8th. Roth Capital analyst J. Aschoff now anticipates that the company will post earnings per share of $1.98 for the year, up from their previous estimate of $1.89. The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.65) per share.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its quarterly earnings data on Thursday, March 28th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.20). The firm had revenue of $13.22 million during the quarter, compared to analysts’ expectations of $13.35 million. Zevra Therapeutics had a negative return on equity of 68.41% and a negative net margin of 167.69%.

A number of other brokerages have also recently issued reports on ZVRA. Maxim Group upped their price objective on shares of Zevra Therapeutics from $12.00 to $18.00 and gave the company a “buy” rating in a research note on Tuesday, April 2nd. William Blair reissued an “outperform” rating on shares of Zevra Therapeutics in a research note on Tuesday, March 12th. HC Wainwright reissued a “buy” rating and issued a $15.00 price target on shares of Zevra Therapeutics in a report on Wednesday, April 3rd. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Zevra Therapeutics in a research report on Monday, April 1st. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $19.50.

Zevra Therapeutics Stock Down 0.3 %

Shares of NASDAQ ZVRA opened at $5.16 on Thursday. The stock has a market capitalization of $224.10 million, a P/E ratio of -4.00 and a beta of 1.87. Zevra Therapeutics has a one year low of $3.89 and a one year high of $7.28. The firm’s 50 day simple moving average is $5.36 and its two-hundred day simple moving average is $5.38. The company has a debt-to-equity ratio of 0.08, a current ratio of 1.18 and a quick ratio of 1.18.

Institutional Trading of Zevra Therapeutics

Several large investors have recently added to or reduced their stakes in the stock. Janney Montgomery Scott LLC bought a new stake in shares of Zevra Therapeutics during the 3rd quarter valued at about $3,250,000. Retirement Planning Co of New England Inc. bought a new position in Zevra Therapeutics in the third quarter worth $1,674,000. Armistice Capital LLC purchased a new position in Zevra Therapeutics during the fourth quarter valued at $1,755,000. Mystic Asset Management Inc. bought a new stake in shares of Zevra Therapeutics during the 3rd quarter valued at $980,000. Finally, Bank of New York Mellon Corp purchased a new stake in shares of Zevra Therapeutics in the 3rd quarter worth about $977,000. Institutional investors own 35.03% of the company’s stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.